1 Ocak 2019 Dergi makalesi Açık Erişim

Oran, D. C.; Lokumcu, T.; Inceoglu, Y.; Akolpoglu, M. B.; Albayrak, O.; Bal, T.; Kurtoglu, M.; Erkan, M.; Can, F.; Bagci-Onder, T.; Kizilel, S.

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 71561, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "affiliation": "Koc Univ, Biomed Sci & Engn, TR-34450 Istanbul, Turkey", 
      "name": "Oran, D. C."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Koc Univ, Biomed Sci & Engn, TR-34450 Istanbul, Turkey", 
      "name": "Lokumcu, T."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Koc Univ, Chem & Biol Engn, TR-34450 Istanbul, Turkey", 
      "name": "Inceoglu, Y."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Koc Univ, Chem & Biol Engn, TR-34450 Istanbul, Turkey", 
      "name": "Akolpoglu, M. B."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Koc Univ, Sch Med, Med Microbiol, TR-34450 Istanbul, Turkey", 
      "name": "Albayrak, O."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Koc Univ, Biomed Sci & Engn, TR-34450 Istanbul, Turkey", 
      "name": "Bal, T."
    }, 
    {
      "@type": "Person", 
      "name": "Kurtoglu, M."
    }, 
    {
      "@type": "Person", 
      "name": "Erkan, M."
    }, 
    {
      "@type": "Person", 
      "name": "Can, F."
    }, 
    {
      "@type": "Person", 
      "name": "Bagci-Onder, T."
    }, 
    {
      "@type": "Person", 
      "name": "Kizilel, S."
    }
  ], 
  "datePublished": "2019-01-01", 
  "description": "Type 1 diabetes (T1D) is an autoimmune disease characterized by destruction of pancreatic beta cells. One of the promising therapeutic approaches in T1D is the transplantation of islets; however, it has serious limitations. To address these limitations, immunotherapeutic strategies have focused on restoring immunologic tolerance, preventing transplanted cell destruction by patients' own immune system. Macrophage-derived chemokines such as chemokine-ligand-22 (CCL22) can be utilized for regulatory T cell (Treg) recruitment and graft tolerance. Stellate cells (SCs) have various immunomodulatory functions: recruitment of Tregs and induction of T-cell apoptosis. Here, we designed a unique immune-privileged microenvironment around implantable islets through overexpression of CCL22 proteins by SCs. We prepared pseudoislets with insulin-secreting mouse insulinoma-6 (MIN6) cells and human SCs as a model to mimic naive islet morphology. Our results demonstrated that transduced SCs can secrete CCL22 and recruit Tregs toward the implantation site in vivo. This study is promising to provide a fundamental understanding of SC-islet interaction and ligand synthesis and transport from SCs at the graft site for ensuring local immune tolerance. Our results also establish a new paradigm for creating tolerable grafts for other chronic diseases such as diabetes, anemia, and central nervous system (CNS) diseases, and advance the science of graft tolerance.", 
  "headline": "Engineering human stellate cells for beta cell replacement therapy promotes in vivo recruitment of regulatory T cells", 
  "identifier": 71561, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "license": "http://www.opendefinition.org/licenses/cc-by", 
  "name": "Engineering human stellate cells for beta cell replacement therapy promotes in vivo recruitment of regulatory T cells", 
  "url": "https://aperta.ulakbim.gov.tr/record/71561"
}